yahoo_financeOriginal article
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Phase 1positiveALLO-316Positive
AI Analysis
Summary
Allogene Therapeutics announced Phase 1 results of ALLO-316 published in the Journal of Clinical Oncology, demonstrating first durable remissions with allogeneic CAR T therapy for metastatic solid tumors. This represents a positive clinical milestone for the company's off-the-shelf CAR T program.
Clinical Trial Data
Phase
Phase 1
Primary Endpoint
Met
Outcome Details
Phase 1 results published in Journal of Clinical Oncology showing first durable remissions following allogeneic CAR T for metastatic solid tumors
Importance:6/10
Sentiment:
0.75
cell therapyCAR-Tallogeneicsolid tumorsclinical datapublication
Related Companies
Read the original article
Published by yahoo_finance on July 15, 2026 12:30 PM